Additionally, studies have shown that SREBP2 and its downstream effector genes are upregulated in prostate cancer following androgen ablation, triggering the formation of androgen-independent (AI) tumors (Ettinger et al., 2004). This evidence concerns the gene SREBF2 and prostate carcinoma.